Q3 Earnings Estimate for Arvinas Issued By HC Wainwright

Arvinas, Inc. (NASDAQ:ARVN) – Equities researchers at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Arvinas in a research report issued to clients and investors on Wednesday, February 12th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.54) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $87.00 target price on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. HC Wainwright also issued estimates for Arvinas’ FY2025 earnings at ($2.13) EPS, FY2026 earnings at ($3.54) EPS, FY2027 earnings at ($2.54) EPS and FY2028 earnings at $2.77 EPS.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.44. During the same period in the previous year, the firm posted ($2.53) earnings per share.

ARVN has been the topic of a number of other research reports. Guggenheim reiterated a “buy” rating and issued a $57.00 price target on shares of Arvinas in a report on Wednesday, February 12th. Stephens began coverage on Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target for the company. Stifel Nicolaus cut their price objective on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. Barclays reduced their price objective on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $82.00 target price (down previously from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Arvinas presently has a consensus rating of “Buy” and a consensus target price of $60.00.

Arvinas Stock Performance

ARVN opened at $18.31 on Monday. Arvinas has a 1 year low of $16.61 and a 1 year high of $53.08. The company’s 50 day simple moving average is $18.88 and its 200 day simple moving average is $23.16. The stock has a market capitalization of $1.26 billion, a PE ratio of -3.92 and a beta of 1.88.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Arvinas by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after acquiring an additional 440 shares during the last quarter. Invesco Ltd. increased its position in shares of Arvinas by 1.6% in the 4th quarter. Invesco Ltd. now owns 37,254 shares of the company’s stock worth $714,000 after purchasing an additional 581 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Arvinas by 0.9% in the 4th quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock valued at $1,685,000 after purchasing an additional 754 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Arvinas by 0.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after purchasing an additional 777 shares during the last quarter. Finally, Bank of Montreal Can lifted its position in shares of Arvinas by 2.7% during the fourth quarter. Bank of Montreal Can now owns 39,407 shares of the company’s stock worth $755,000 after purchasing an additional 1,044 shares during the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.